REG - Ergomed plc - Exercise of Share Options and Total Voting Rights

ErgomedAnnouncement

04/08/2020 07:01

RNS Number : 0055V
  
Ergomed plc
  
04 August 2020
  
 

 PRESS RELEASE
 
 
Exercise of Share Options and Total Voting Rights
 
 
Guildford, UK - 4 August 2020: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, announces that, following an exercise of share options, application has been made to AIM for the admission of 50,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").
 
Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 6 August 2020.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.
 
Following Admission, the total number of ordinary shares with voting rights in issue will be 48,411,442. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
 
 
ENDS
 
Enquiries:
 



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)








Richard Barfield (Chief Financial Officer)


















Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Sue Stuart 


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser

















 
 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
MSCPJMBTMTJMTRM